Urovant Sciences Ltd (UROV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
(Values in U.S. thousands)
| 03-2020 | 03-2019 | 03-2018 | 03-2017 | |
| Cash Flows From Operating Activities | ||||
| Net Income | -146,745 | -111,346 | -37,074 | -26,970 |
| Depreciation Amortization | 246 | 180 | 12 | N/A |
| Accounts payable and accrued liabilities | -336 | 1,092 | 817 | 16 |
| Other Working Capital | 18,443 | -2,202 | -227 | 858 |
| Other Operating Activity | 26,308 | 3,240 | 2,386 | 840 |
| Operating Cash Flow | $-102,084 | $-109,036 | $-34,086 | $-25,256 |
| Cash Flows From Investing Activities | ||||
| PPE Investments | -769 | -593 | -522 | N/A |
| Investing Cash Flow | $-769 | $-593 | $-522 | $N/A |
| Cash Flows From Financing Activities | ||||
| Debt Issued | 117,500 | 15,000 | N/A | N/A |
| Debt Repayment | -47,854 | N/A | N/A | N/A |
| Common Stock Issued | 796 | 132,931 | N/A | N/A |
| Other Financing Activity | -1,505 | 40,700 | 37,035 | 30,024 |
| Financing Cash Flow | $68,937 | $188,631 | $37,035 | $30,024 |
| Beginning Cash Position | 86,196 | 7,194 | 4,767 | N/A |
| End Cash Position | 52,280 | 86,196 | 7,194 | 4,768 |
| Net Cash Flow | $-33,916 | $79,002 | $2,427 | $4,768 |
| Free Cash Flow | ||||
| Operating Cash Flow | -102,084 | -109,036 | -34,086 | -25,256 |
| Capital Expenditure | -769 | -593 | -522 | N/A |
| Free Cash Flow | -102,853 | -109,629 | -34,608 | -25,256 |